WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206474
Description: RSM-932A, also known as TCD-717, is a novel anticancer drug targeting the human choline kinase alpha, an enzyme involved in increased lipid metabolism of cancer cells. RSM-932A appears to have an altogether novel mechanism of inhibition and is synergistic with respect to both choline and ATP. RSM-932A have in vitro inhibitory activity in the low nanomolar range. RSM-932A significantly reduced parasitemia and induced the accumulation of trophozoites and schizonts, blocking intraerythrocytic development and interfering with parasite egress or invasion, suggesting a delay of the parasite maturation stage.
MedKoo Cat#: 206474
Chemical Formula: C46H38Br2Cl2N4
Molecular Weight: 877.546
Elemental Analysis: C, 62.96; H, 4.36; Br, 18.21; Cl, 8.08; N, 6.38
RSM-932A (TCD-717) is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: RSM-932A; RSM 932A; RSM932A; TCD 717; TCD717; TCD-717.
IUPAC/Chemical Name: 1,1'-([1,1'-biphenyl]-4,4'-diylbis(methylene))bis(4-((4-chlorophenyl)(methyl)amino)quinolin-1-ium) bromide
InChi Key: DGBVSSXGHKAASQ-UHFFFAOYSA-L
InChi Code: InChI=1S/C46H38Cl2N4.2BrH/c1-49(39-23-19-37(47)20-24-39)43-27-29-51(45-9-5-3-7-41(43)45)31-33-11-15-35(16-12-33)36-17-13-34(14-18-36)32-52-30-28-44(42-8-4-6-10-46(42)52)50(2)40-25-21-38(48)22-26-40;;/h3-30H,31-32H2,1-2H3;2*1H/q+2;;/p-2
SMILES Code: CN(C1=CC=C(Cl)C=C1)C(C2=C3C=CC=C2)=CC=[N+]3CC4=CC=C(C5=CC=C(C[N+]6=CC=C(N(C7=CC=C(Cl)C=C7)C)C8=C6C=CC=C8)C=C5)C=C4.[Br-].[Br-]
The following data is based on the product molecular weight 877.546 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Lacal JC, Campos JM. Preclinical characterization of RSM-932A, a novel
anticancer drug targeting the human choline kinase alpha, an enzyme involved in
increased lipid metabolism of cancer cells. Mol Cancer Ther. 2015 Jan;14(1):31-9.
doi: 10.1158/1535-7163.MCT-14-0531. Epub 2014 Dec 8. PubMed PMID: 25487918.
2: Zimmerman T, Moneriz C, Diez A, Bautista JM, Gómez Del Pulgar T, Cebrián A,
Lacal JC. Antiplasmodial activity and mechanism of action of RSM-932A, a
promising synergistic inhibitor of Plasmodium falciparum choline kinase.
Antimicrob Agents Chemother. 2013 Dec;57(12):5878-88. doi: 10.1128/AAC.00920-13.
Epub 2013 Sep 16. PubMed PMID: 24041883; PubMed Central PMCID: PMC3837925.
850807-63-5 ( RSM-932A)
850993-73-6 ( RSM-932A cation)